BRADSHER NEAL C 4
4 · Lineage Cell Therapeutics, Inc. · Filed Jun 25, 2021
Insider Transaction Report
Form 4
Bradsher Neal C
10% Owner
Transactions
- Exercise/Conversion
OPTION TO PURCHASE COMMON SHARES
2021-06-25−24,720→ 0 totalExercise: $2.20Exp: 2021-06-30→ COMMON SHARES (24,720 underlying) - Exercise/Conversion
Common Shares
2021-06-25$2.20/sh+24,720$54,384→ 87,628 total
Holdings
- 40,000
OPTION TO PURCHASE COMMON SHARES
Exercise: $0.83Exp: 2030-07-01→ COMMON SHARES (40,000 underlying) - 24,720
OPTION TO PURCHASE COMMON SHARES
Exercise: $2.55Exp: 2022-06-30→ COMMON SHARES (24,720 underlying) - 49,440
OPTION TO PURCHASE COMMON SHARES
Exercise: $1.67Exp: 2023-06-30→ COMMON SHARES (49,440 underlying) - 34,005,379(indirect: See Footnote)
Common Shares
Footnotes (2)
- [F1]These securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be indirectly beneficially owned by: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher (the "Reporting Person"), as President of Broadwood Capital. Each of Broadwood Capital and the Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that Broadwood Capital or the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F2]These options are currently exercisable.